Development of non-invasive neuromodulation treatment for depressive disorder by violet light - double-blind, randomized, crossover study

Kitahata Ryosuke0 sites70 target enrollmentAugust 19, 2021

Overview

No summary available.

Registry

who.int

Start Date

August 19, 2021

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Kitahata Ryosuke

•1\)Patients diagnosed with major depressive disorder according to DSM\-5 diagnostic criteria
•2\)Patients with mild depression with a MADRS score between 15 and 19
•3\)Patients who can spend 3 hours wearing research equipment with naked eyes (or contact lenses that meet certain criteria\*)
•4\)Outpatient
•5\)Men and women aged 20 to 74 at the time of obtaining consent
•6\)Patients who have written informed consent to participate in this study.
•\* Contact lenses with UV protection and colored contact lenses cannot be used

•1\)Patients with cerebral organic diseases (intermediate intracranial organic lesions or neurodegenerative diseases, etc.)
•2\)Patients with a history of seizures or epilepsy
•3\)Patients with a psychiatric diagnosis other than depression
•4\)Patients who are receiving psychotherapy in 1 month prior to the screening
•5\)Patients who are difficult to participate in this study due to mental instability
•6\)Patients at high risk of suicide such as suicide intent and attempt
•7\)Patients with serious or unstable physical illness
•8\)Patients with severe cataract (nuclear sclerosis grade 3 or higher)
•9\)Patients who underwent ophthalmic surgery within 6 months before obtaining consent.
•10\)Patients with retinal abnormalities such as serous retinal detachment and retinal hemorrhage